DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Choksi Laboratories Ltd?

Choksi Laboratories Ltd has a price-to-earnings (PE) ratio of 42.8 in the Healthcare Services sector.

What is the market capitalisation of Choksi Laboratories Ltd?

Choksi Laboratories Ltd has a market capitalisation of approximately ₹85 crore.

Choksi Laboratories Ltd

CHOKSILABORATORIESLTD·NSE·Healthcare Services

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare Services · Healthcare Service Provider

A steady, established business

52W₹82

₹237-53%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹85 Cr

P/E Ratio

42.80Expensive

P/B Ratio

3.28

EPS

₹2.18

Book Value

₹36.72

ROE

6.10%Weak

ROCE

9.20%Weak

Dividend Yield

0.00%

Debt / Equity

1.20Elevated

Face Value

₹10.00

52W High

₹236.70

52W Low

₹81.85

Sector

Healthcare Services

Industry

Healthcare Service Provider

Expensive

None moatMedium uncertainty

Fair value estimate

₹34

No recent traded price

BearFair valueBull

₹29₹34₹39

/100

Business quality — Watch the fundamentals

Growth 50Profitability 7Efficiency 6Valuation 29

Plain English

Our view

A steady, established business
Weak returns on equity (6%)

How we got there

Fair value methods

Residual income

6% ROE fading to 14% over ~3 yrs, on ₹37 book

₹33

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹36

Analyst target

No analyst coverage

—

Blended fair value₹34

What the numbers say

Investment thesis

Bull case

No standout positives from the current metrics.

Bear case

Weak returns on equity (6%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

42.8Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

6.1%Weak

Above 15% is considered healthy for Indian equities

ROCE

9.2%Weak

Above 18% means capital is working hard

Debt/Eq

1.20Elevated

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹85 Cr

P/B

3.28

EPS

₹2.18

Div Yield

—

What changed

Recent changes

Foreign investors+0.3% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 42.8×

Growth

Steady

+10% rev CAGR

Profitability

Modest

6.1% ROE

Financial health

Leveraged

D/E 1.20

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+10.1%

+12.4%

10Y

+6.3%

Profit

-11.2%

—

10Y

+12.1%

EPS

-29.9%

—

10Y

+4.4%

Profile

Cons

Stock is trading at 3.32 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has low interest coverage ratio.
Promoter holding is low: 31.5%
Company has a low return on equity of 5.97% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.34 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

31%

Promoter

Promoters

31.5%0.00

Public

49.4%+0.37

FII / FPI

6.0%+0.34

DII

0.0%0.00

Others

13.1%

Total shareholders

4,011-46 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter31.48%

FII6.03%

Public49.44%

Others13.05%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1982, Choksi Laboratories Ltd provides contract testing and analytical services.[1]